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1. Introduction
  Malaria is a common and severe tropical disease. It is 
caused by a protozoan belonging to the genus Plasmodium. 
Malaria is attributed to high mortality and morbidity in 
tropical countries and affects around 100 countries of the 
world. Nearly 1 million people die and almost 300 million 
symptomatic illnesses occur due to malaria annually. Over 
the past 50 years, the resistance to commonly used anti-
malarial agents has significantly hindered malaria control[1]. 
The problem of antimalarial resistance is more pronounced 
with Plasmodium falciparum[2]. So the development of anti- 
malaria drugs is urgently needed to meet the prevailing 
challenges. Identification of potential drug targets is the 
first step in the process of modern drug development.
  Whole genome sequences of a number of organisms and the 
completion of the human genome project provide methods for 
predicting potential drug targets against threatening human 
pathogens. The search for potential drug targets relies 
on the assumption that the potential target must play an 
essential role in the pathogen's survival, because chemical 
inhibition of non-essential genes is unlikely to result in the 
death of the infectious agent. At the same time, this target 
should have non-human orthologous targets. So this would 
have little or no effect on human[3]. Zhang and Lin[4] have 
compiled information on experimentally proven essential 
genes from some prokaryotes and eukaryotes via Database 
of Essential Genes (DEG). This resource facilitates drug 
targets development by seeking non-human targets in the 
DEG. Based on the criteria that a target should be essential 
protein for a given pathogen, and should be no-homologous 
to human host, putative drug targets have been successfully 
identified in Pseudomonas aeruginosa, Helicobacter pylori, 
Burkholderia pseudomallei and Aeromonas hydrophila[5]. 
  This study aims to identify novel drug targets for treatment 
of Plasmodium falciparum. 
Objective: To identify novel drug targets for treatment of Plasmodium falciparum. Methods: 
Local BLASTP were used to find the proteins non-homologous to human essential proteins as 
novel drug targets. Functional domains of novel drug targets were identified by InterPro and 
Pfam, 3D structures of potential drug targets were predicated by the SWISS-MODEL workspace. 
Ligands and ligand-binding sites of the proteins were searched by Ef-seek. Results: Three 
essential proteins were identified that might be considered as potential drug targets. AAN37254.1 
belonged to 1-deoxy-D-xylulose 5-phosphate reductoisomerase, CAD50499.1 belonged 
to chorismate synthase, CAD51220.1 belonged to FAD binging 3 family, but the function of 
CAD51220.1 was unknown. The 3D structures, ligands and ligand-binding sites of AAN37254.1 
and CAD50499.1 were successfully predicated. Conclusions: Two of these potential drug targets 
are key enzymes in 2-C-methyl-d-erythritol 4-phosphate pathway and shikimate pathway, 
which are absent in humans, so these two essential proteins are good potential drug targets. The 
function and 3D structures of CAD50499.1 is still unknown, it still need further study.
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2. Materials and methods
2.1. Comparative genome analysis
  Protein sequences of Homo sapiens and Plasmodium 
falciparum 3D7 were downloaded from the National Center 
for Biotechnology Information (NCBI, ftp://ftp.ncbi.nlm.
nih.gov/genomes/). The essential proteins of Arabidopsis 
thaliana, Aspergillus fumigatus, Caenorhabditis elegans, 
Danio rerio, Drosophila melanogaster, Mus musculus, 
Saccharomyces cerevisiae were downloaded from DEG 
(http://tubic.tju.edu.cn/deg/). The Plasmodium falciparum 
protein sequences were subjected to local BLASTP analysis 
against DEG essential protein sequences to identify 
essential proteins at an E-value cutoff of 10-10. Bit score and 
percentage of identity at amino acid level were considered 
100% and >35%, respectively. The results were subjected 
to local BLASTP analysis against protein sequences of Homo 
sapiens at an expectation E-value cutoff of 10-3 to identify 
non-homologous sequences.
2.2. Identified functional domains
  Functional domains were identified by InterPro (http://
www.ebi.ac.uk/interpro/InterPro)[6] and Pfam (http://pfam.
sanger.ac.uk/ Pfam)[7]. 
2.3. Homology modeling for 3D structure of potential drug 
targets
  The 3D structures of potential drug targets were predicated 
by SWISS-MODEL workspace (http://swissmodel.expasy.
org/workspace). The generated structural models were 
visualized using the Pymol viewer software. The quality 
of the model was evaluated using the PROCHECK program 
(http://nihserver.mbi.ucla.edu/SAVES_3/) and assessed using 
the Ramachandran plot. Ligands and ligand-binding sites 
of the proteins were searched by Ef-seek (http://ef-site.hgc.
jp/eF-seek/). 
3. Results
3.1. Essential non-human homologs proteins of Plasmodium 
falciparum 
  
  A total of 561 essential proteins and 3 proteins (AAN37254.1, 
CAD50499.1, CAD51220.1) belonged to non-human homologue 
essential proteins were identified. 
3.2. Protein functional analysis 
  The InterPro and Pfam search indicated that AAN37254.1 
be longed  to  1-deoxy- D-xy lu lose  5-phospha te 
reductoisomerase (DXR), CAD50499.1 belonged to chorismate 
synthase, CAD51220.1 belonged to FAD binging 3 family, but 
the function of CAD51220.1 was unknown.
3.3. Structure modeling and validation of the generated 
model 
  The 3D structures of AAN37254.1 and CAD50499.1 were 
predicated as Figure 1. The quality of the model was 
evaluated using the PROCHECK program and assessed 
using the Ramachandran plot. It was evident from the 
Ramchandran plot that the predicted model of AAN37254.1 
had 91.6%, 7.3%, and 0.3% residues in the most favorable 
regions, the allowed regions, and the disallowed regions, 
respectively. The predicted model of CAD50499.1 had 
81.0%, 13.8%, and 1.5% residues in the most favorable 
regions, the allowed regions, and the disallowed regions, 
respectively. Such percentage distribution of the protein 
residues determined by Ramachandran plot showed that 
the predicted models were of good qualities. No homologous 
protein with a 3D structure of CAD51220.1 was found, so the 
3D structure of CAD51220.1 couldn't be predicted. 
Figure 1. Predicted 3D structure.
a: AAN37254.1, b: CAD50499.1.
3.4. Ligands and ligand-binding sites
  A total of 3 top ligand-binding residue sites in AAN37254.1 
were identified using Ef-seek. All had the ligands of 
NDP, and ligand-binding residues were very similar in 
AAN37254.1 (Figure 2). In CAD50499.1, these 3 top ligands 
were C8E, PIE and CLA, and ligand-binding residues and 
ligands were showed as Figure 3. The ligands of CLA was 
not buried in the protein but exposed outside. It was large 
in size and could not stay comfortably in the incommodious 
pocket.
Figure 2. The ligands and ligand-binding sites of AAN37254.1.
The backbone of protein is shown as cartoon. The ligand (NDP) is 
shown as spheres in red, The ligand-binding sites are shown as 
spheres in green. 
(a) ligand-binding sites: 84aa, 86-89aa, 92aa, 113-117aa, 136aa 
162aa, 180-183aa, 185aa, 203-206aa, 231-233aa, 296-302aa, 
305aa, 311aa, 314aa, 315aa, 360aa; (b) ligand-binding sites: 84aa, 
86-89aa, 91aa, 92aa, 113-117aa, 120aa, 136aa, 137aa, 162aa, 180-
182aa, 185aa, 203-206aa, 231-233aa, 296-302aa, 311aa, 315aa, 
360aa;  (c) ligand-binding sites: 84aa, 86-89aa, 92aa, 113-117aa, 
136aa, 162aa, 180-183aa, 185aa, 188aa, 302-206aa, 231-233aa, 
296-302aa, 305aa, 311aa, 314aa, 315aa, 360aa. 
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Figure 3.  The ligands and ligand-binding sites of CAD50499.1.
The backbone of protein is shown as cartoon. The ligand is shown as 
spheres in red, The ligand-binding sites is shown as spheres in green. 
(a) ligand: C8E . ligand-binding sites:326aa, 330aa, 338-340aa, 
342-344aa, 346aa, 347aa, 349aa, 351aa, 354aa, 355aa, 436aa, 
437aa; (b) ligand: PIE. ligand-binding sites: 382aa, 383aa, 385-39aa, 
399 400; (c) ligand: CLA. ligand-binding sites: 379aa, 380aa, 382aa, 
383aa, 386aa, 387aa, 389aa, 400-404aa, 407aa.
4. Discussion
  Novel drug targets are required in order to design new 
drugs against parasites. The search for potential drug 
targets has increasingly relied on genomic approaches. The 
potential drug targets should be a molecule that is essential 
to the parasites and have no non-human orthologous 
targets, for which inhibition of essential genes would kill 
the parasite but have no effect on human homologue. Based 
on this criteria, we had found 3 potential drug targets of 
Plasmodium falciparum.
  Isoprenoids, one of the largest groups of natural compounds, 
have a variety of roles in respiration, photosynthesis, 
membrane structure, allelochemical interactions, and growth 
regulation[8,9]. Isopentenyl diphosphate is a precursor of 
various isoprenoids and is produced by the 2-C-methyl-d-
erythritol 4-phosphate (MEP) pathway in plastids of plant 
and protozoa[10,11]. The MEP pathway is absent from humans, 
and DXR is a key enzyme in the MEP pathway. DXR has 
reported to be the target of fosmidomycin[12], so it will be 
a promising drug target for anti-malarial. The shikimate 
pathway is essential in algae, plants, bacteria, protozoa and 
fungi, and is also absent from mammals. The absence of 
the pathway in mammals makes them potential targets for 
development of new therapy against infectious diseases[13], 
such as Plasmodium falciparum. The enzymes of shikimate 
pathway are good candidates for development of new 
therapies against Plasmodium falciparum. The last enzyme 
of this pathway is chorismate synthase, which catalyzes the 
conversion of the 5-enolpyruvylshikimate-3-phosphate 
to chorismate. So chorismate synthase (CAD50499.1) of 
Plasmodium falciparum will be a good candidate for drug 
targets. Although CAD51220.1 is of unknown function, 
further bioinformatics analysis on this protein might shed 
some light on a new drug targets. 
  3D structure and/or structure complex with ligands and 
ligand-binding sites would enhance the druggability value 
by facilitating a structure based drug design strategy. 
Prediction of ligand-binding sites is a fundamental step in 
order to investigate the molecular recognition mechanism 
and function of a protein. Structural analysis and 
computational modeling of ligand-binding sites bring key 
information to designing drugs and annotating proteins[14,15]. 
We had found the ligands and the ligand-binding sites 
of DXR and chorismate synthase, the ligand-binding 
sites would be the sites for the drugs binding. All of these 
information about the drug targets would help the design of 
the drugs.
  Targeting an essential protein for the parasite may provide 
an effective way to control infection. Comparative genome 
analysis is a highly efficient approach for identifying 
potential proteins that can be used as potential targets for 
effective drug designing against pathogenic organisms. 
Here, we have identified three potential drug targets of 
Plasmodium falciparum, and analyzed the function and 
ligands and ligand-binding sites of DXR and chorismate 
synthase. DXR and chorismate synthase fit for drug targets, 
and the druggability of CAD51220.1 needs further study. 
These targets should be experimentally validated for their 
role in Plasmodium falciparum drug targets. 
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